



# Stocking of AGILUS<sup>®</sup>

## (dantrolene sodium hemiheptahydrate)

Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Adverse events should also be reported to Norgine Pharmaceuticals Ltd on: Tel: +44 (0)1895 826 606 Email: [medinfo@norgine.com](mailto:medinfo@norgine.com)



Please scan or click the QR code at the end of this document to access prescribing information.

In combination with adequate support measures, AGILUS<sup>®</sup> is indicated for the treatment of malignant hyperthermia in adults and children of all ages.

# How to make sure you have enough AGILUS® to maintain patient safety

---


## Ensuring sufficient availability of AGILUS® is essential.<sup>2</sup>

Insufficient stock could mean a lack of appropriate and timely treatment, which can lead to serious consequences for patients and hospitals:<sup>2</sup>

- Inability to rapidly access treatment during an MH crisis.
- Discontinuation of elective anaesthetic services using inhalational anaesthetics or succinylcholine.

## Guidelines from the European Malignant Hyperthermia Group (EMHG)<sup>2</sup>

- Wherever volatile anaesthetics or succinylcholine are used: A minimum of 720 mg of dantrolene (equivalent to 6 vials of AGILUS®) should be immediately available.




# Understanding how much AGILUS® your hospital needs

When calculating required stock levels, institutions should carefully consider what other sources of AGILUS® are available locally, and also the time required to obtain them.<sup>2</sup>

## Ensuring sufficient availability of AGILUS® is essential.<sup>2</sup>

EMHG recommendation for AGILUS® stocking:



# Prescribing information

---

**Click or scan to view Prescribing information**

Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Adverse events should also be reported to Norgine Pharmaceuticals Ltd on:  
Tel: +44 (0)1895 826 606 Email: [medinfo@norgine.com](mailto:medinfo@norgine.com)

Please refer to the Summary of Product Characteristics for full details on preparation and administration.



**References:**

1. Agilus. Summary of product characteristics.
2. Glahn KPE, et al. *British Journal of Anaesthesia*. 2020;125(2):133-140.